These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36926054)

  • 1. Prognosis of Primary Liver Cancer Based on LI-RADS Classification with Extracellular Agent-Enhanced MRI.
    Li Y; Ni X; Liu X; Yang C; Wang Y; Lu X; Zhou C
    J Hepatocell Carcinoma; 2023; 10():399-411. PubMed ID: 36926054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
    Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
    Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
    Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
    Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
    Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
    Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
    Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
    Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
    Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
    Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.
    Liu X; Ni X; Li Y; Yang C; Wang Y; Ma C; Zhou C; Lu X
    Front Oncol; 2022; 12():934045. PubMed ID: 35847955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS.
    Cannella R; Dioguardi Burgio M; Beaufrère A; Trapani L; Paradis V; Hobeika C; Cauchy F; Bouattour M; Vilgrain V; Sartoris R; Ronot M
    JHEP Rep; 2021 Dec; 3(6):100380. PubMed ID: 34825155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma.
    Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH
    J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
    Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
    Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of LI-RADS category on MRI in patients with primary hepatic lymphoepithelioma-like carcinoma.
    Pan YJ; Liu W; Qiu QX; Miao SL; Zeng MS; Shan Y; Lin J; Xu PJ
    Eur Radiol; 2023 Sep; 33(9):5993-6000. PubMed ID: 37014407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LI-RADS Category on MRI Is Associated With Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study.
    Hwang JA; Lee S; Lee JE; Yoon J; Choi SY; Shin J
    J Magn Reson Imaging; 2023 Mar; 57(3):930-938. PubMed ID: 35833798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic and MRI features of combined hepatocellular-cholangiocarcinoma in patients with or without cirrhosis.
    Yoon J; Hwang JA; Lee S; Lee JE; Ha SY; Park YN
    Liver Int; 2021 Jul; 41(7):1641-1651. PubMed ID: 33503328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
    Kim SS; Lee S; Kim MJ
    Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma.
    Zhou Y; Yin S; Zhao L; Zhang X; Li M; Ding J; Yan K; Jing X
    Front Oncol; 2022; 12():897090. PubMed ID: 35651804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Imaging Reporting and Data System Category on Magnetic Resonance Imaging Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation Within the Milan Criteria: A Multicenter Study.
    Lee S; Kim KW; Jeong WK; Jeong SY; Hwang JA; Choi JS; Lee SG; Joh JW
    Ann Surg Oncol; 2021 Oct; 28(11):6782-6789. PubMed ID: 33751296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Early Recurrence of Hepatocellular Carcinomas Categorized as LR-M: Comparison with Those Categorized as LR-4 or 5.
    Shin J; Lee S; Kim SS; Chung YE; Choi JY; Park MS; Kim MJ
    J Magn Reson Imaging; 2021 Nov; 54(5):1446-1454. PubMed ID: 33891790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.